DexCare, a patient access software company that spun out of the Providence health system, said on September 21, 2026 that it had acquired Mila Health, a startup that builds AI agents to contact patients by phone, text and chat.
The companies did not disclose the price or other terms. DexCare said Mila's agents now run on its own scheduling data model and that the combined product is meant to move its AI beyond booking appointments into wider care coordination, such as getting patients ready for procedures and following up after they go home.
GeekWire described the deal as a combination of two Seattle-area health tech companies. It is DexCare's second acquisition, after it bought Womp in 2022.
What Mila Health built
Mila sells AI agents that reach out to patients on behalf of providers and payers. DexCare gave examples of the work: calling patients who are overdue for a visit, explaining what a procedure requires, and checking in after discharge.
Mila is built as an API-first system that customers can configure and embed in their existing workflows, and DexCare said agents could be launched in hours. Customers can also trace how an agent reached each decision and when it handed a case to a person.
Mila reported several results from its production deployments. Its agents reached a 54% response rate in outbound outreach, which it said was 80% higher than manual call centers, and it said they cut no-show rates by 50% and increased revenue by 18%. Those figures come from the company and were not independently verified.
Shailu Verma, Mila's co-founder and chief executive, said healthcare could not depend on general-purpose large language models because they were unpredictable and could not be audited.
“Healthcare can’t rely on out-of-the-box large language models because they’re unpredictable and can’t be audited.”
Why DexCare is buying
DexCare's core product is what it calls an access data model: a set of rules that pulls together credentialing, referral requirements, insurance and scheduling protocols, which often differ by location, provider and scheduler. The company says this model has been used for more than 10 million bookings.
The argument for the deal is that an AI agent needs that context to act correctly. Matt Blosl, DexCare's chief executive, said many health systems found that building the infrastructure for agents, scaling pilots and controlling what the agents could do was too much to manage, and that most agents did not understand how a health system's service lines, staff and locations fit together. He said Mila would act on DexCare's data, from contacting overdue patients to walking them through procedure requirements.
Dr. Peter Chang, chief transformation officer at Tampa General Hospital, a DexCare customer, said DexCare had codified 260 of the hospital's scheduling policies and found more than 50 gaps in them.
The companies and their funding
DexCare spun out of Providence Health in 2021 and has raised $146 million, including a $75 million Series C led by ICONIQ Growth in 2023. It says its software serves 57 million patients across all 50 states, and its customers include Kaiser Permanente, Piedmont, Texas Health Resources and Tampa General.
Mila's own funding history was not disclosed in the announcement, and neither company said how many Mila employees would join DexCare or whether the Mila brand would remain in use.
A crowded market for AI patient outreach
Health systems have been testing AI agents for scheduling, reminders and follow-up calls, work that has traditionally been done by call center staff. DexCare's pitch, in its own words, is that the era of buying one tool at a time for each access problem is over, and that agents need to sit on top of a governed scheduling system rather than operate on their own.
By adding Mila, DexCare now offers both the scheduling rules and the agents that act on them, which puts it in competition with standalone AI agent vendors selling into the same hospitals.
